Rite Aid Announces Availability of Opill at All Locations
Rite Aid Announces Availability of Opill at All Locations
The first FDA-approved over-the-counter daily birth control pill in the U.S. is now on shelves, available for purchase
Rite Aid Corporation (OTC: RADCQ) today announced Opill, the first daily oral contraceptive FDA-approved for purchase without a prescription, is now available in all stores. Opill is a progestin-only, daily oral contraceptive (birth control pill) that’s safe and effective when used as directed to help prevent pregnancy.
Opill over-the-counter birth control pills are available at Rite Aid for the suggested retail price of $19.99 for a one-month supply and $49.99 for a three-month supply. Both options are available for purchase at Rite Aid stores nationwide and online at RiteAid.com.
“Carrying an over-the-counter FDA-approved birth control pill is an important step in increasing access to reproductive health products and services for women,” said Karen Staniforth, Senior Vice President, Chief Pharmacy Officer at Rite Aid. “Rite Aid remains committed to providing convenient access to customers for all of their health and wellness needs.”
There are no restrictions for purchasing Opill. Rite Aid pharmacists are available to answer any customer questions about Opill.
About Rite Aid Corporation
Rite Aid is a full-service pharmacy committed to improving health outcomes. Rite Aid is defining the modern pharmacy by meeting customer needs with a wide range of solutions that offer convenience, including retail and delivery pharmacy, as well as services offered through our wholly owned subsidiary Bartell Drugs. Regional chain Bartell Drugs has supported the health and wellness needs in the Seattle area for more than 130 years. Rite Aid employs nearly 6,000 pharmacists and operates more than 1,700 retail pharmacy locations across 16 states. For more information, visit www.riteaid.com.
Catherine Carter
Rite Aid
717-975-5718
press@riteaid.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240404214626/en/
-
After Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
Is ServiceNow Stock a Buy After Earnings and Its Investor Day?
-
3 Stocks to Buy and 3 Stocks to Sell After Earnings
-
Markets Brief: Is It Really a Surprising Quarter for Earnings?
-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Occidental Earnings: CrownRock Transaction Should Still Close, but Not Until the Third Quarter
-
After Earnings, Is Apple Stock a Buy, a Sell, or Fairly Valued?
-
Uber Earnings: Network Effect Continues to Drive Profitable Growth for Uber
-
Undervalued by 28%, This Stock Is a Buy for Patient Investors
-
10 Best Growth Stocks to Buy for the Long Term
-
The Best Technology Stocks to Buy
-
After Earnings, Is Coke Stock a Buy, a Sell, or Fairly Valued?
-
Disney Earnings: Improved Streaming Results Come at the Expense of Continued Linear Weakness